Pan Asia Chemical Corp. AI Stock Analysis
Pan Asia Chemical Corp. (4707) AI Stock Analysis
Pan Asia Chemical Corp.
(TPEx:4707)
Pan Asia Chemical scores below average, driven primarily by a deteriorating core business: shrinking revenue, negative gross margin and three straight years of operating losses, with reported profits sourced almost entirely from non-operating income. Its fortress-like balance sheet — low leverage, falling debt and equity covering over 70% of assets — provides meaningful downside protection and is the main offset. Technicals reinforce caution, with the share price trading well below its short- and medium-term moving averages and a negative MACD, though oversold readings hint at possible near-term stabilisation. Valuation at nearly 21x earnings looks full relative to earnings quality, and the sub-1% dividend yield offers limited compensation. Evidence of margin recovery and a return to operating profitability would be needed to justify a higher score.
Pan Asia Chemical Corp. (4707) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 11.86B
- Dividend Yield
- 0.92%
- Average Volume (3M)
- 3.17M
- Price to Earnings (P/E)
- 21.4
- Beta (1Y)
- 0.79
- Revenue Growth
- -9.16%
- EPS Growth
- 67.21%
- Country
- TW
- Employees
- 109
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals - Specialty
Pan Asia Chemical Corp. Business Overview & Revenue Model
Company Description
Pan Asia Chemical Co. (PACC), a Taiwanese firm, specializes in the manufacturing, sale, and distribution of diverse chemical compounds within Taiwan and internationally. Its extensive product portfolio features a wide array of surfactants, including...
Pan Asia Chemical Corp. Financial Statement Overview
Summary
A strong balance sheet (score 68) is the main support: debt-to-equity has fallen to 0.36, equity funds roughly 71% of the NT$8.68bn asset base, and total debt continues to decline. However, the core business is deteriorating — revenue has contracted from NT$1.83bn in 2022 to NT$1.34bn in 2025, gross margin has fallen from 14.7% to negative 2.4%, and operating losses have been posted for three consecutive years (income statement score 32). Reported net income of NT$360m comes almost entirely from non-operating sources, a significant earnings-quality concern. Cash flow (score 40) improved in 2025 to NT$86m operating and NT$73m free cash flow, but remains a fraction of the NT$406m generated in 2022, with minimal capital reinvestment.
Income Statement
32NegativeBalance Sheet
68PositiveCash Flow
40Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.29B | 1.34B | 1.44B | 1.32B | 1.83B | 1.73B |
| Gross Profit | 20.81M | -32.77M | 19.40M | 91.63M | 268.11M | 193.59M |
| EBITDA | 159.44M | -54.60M | 38.30M | 461.40M | 545.34M | 438.98M |
| Net Income | 520.75M | 360.26M | 381.79M | 347.28M | 402.10M | 342.98M |
Balance Sheet | ||||||
| Total Assets | 10.89B | 8.68B | 8.69B | 8.41B | 8.48B | 8.79B |
| Cash, Cash Equivalents and Short-Term Investments | 574.25M | 571.16M | 591.65M | 505.14M | 564.25M | 592.69M |
| Total Debt | 2.22B | 2.24B | 2.38B | 2.06B | 2.36B | 2.63B |
| Total Liabilities | 2.62B | 2.47B | 2.66B | 2.40B | 2.80B | 2.96B |
| Stockholders Equity | 8.27B | 6.21B | 6.03B | 6.01B | 5.68B | 5.83B |
Cash Flow | ||||||
| Free Cash Flow | 152.02M | 73.17M | 38.18M | 25.90M | 398.21M | 146.66M |
| Operating Cash Flow | 161.56M | 86.36M | 40.78M | 36.91M | 406.18M | 158.64M |
| Investing Cash Flow | 124.45M | 94.87M | -175.77M | 264.07M | -58.78M | -105.92M |
| Financing Cash Flow | -230.32M | -226.05M | 203.97M | -366.34M | -320.91M | -169.06M |
Pan Asia Chemical Corp. Peers Comparison
Overall Rating
TW:650969Neutral
TW:170865Neutral
TW:475558Neutral
TW:130446Neutral
TW:470745Neutral
TW:172739Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | TWD 9.02B | 12.96 | ― | 3.23% | 2.00% | 57.23% | |
| 65Neutral | TWD 11.22B | 11.02 | ― | 3.52% | 3.55% | 34.35% | |
| 58Neutral | TWD 12.34B | 27.45 | ― | 3.05% | -11.09% | 37.46% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 46Neutral | TWD 12.12B | -6.20 | ― | 1.32% | -9.36% | 30.01% | |
| 45Neutral | TWD 11.15B | 21.39 | ― | 0.92% | -9.16% | 67.21% | |
| 39Underperform | TWD 11.75B | 121.53 | ― | 0.18% | 20.16% | 962.24% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4707 | Pan Asia Chemical Corp. | 27.30 | 17.85 | 188.80% | |
| TW:1304 | USI Corporation | 11.40 | 0.23 | 2.03% | |
| TW:1708 | Sesoda Corporation | 45.40 | 14.45 | 46.66% | |
| TW:1727 | Chung Hwa Chemical Industrial Works Ltd. | 84.10 | 47.51 | 129.83% | |
| TW:4755 | San Fu Chemical Co., Ltd. | 121.50 | 17.34 | 16.65% | |
| TW:6509 | Taiwan Hopax Chemicals Manufacturing Co. Ltd. | 43.20 | 10.94 | 33.93% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
